Gallbladder adenocarcinoma

Summary

Gallbladder adenocarcinoma (MONDO:0006215) is a disease and 16 clinical trials. Top therapeutic interventions include bevacizumab, sorafenib, and selumetinib. A subtype of gallbladder carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 16

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gallbladder adenocarcinoma
Mondo ID	MONDO:0006215
EFO	EFO:1000262
DOID	DOID:3500
ICD-11	15874829
NCIT	C9166
UMLS	C0279651
MedGen	76009
GARD	0024333
Anatomy (UBERON)	UBERON:0002110
Is cancer (heuristic)	no

Also known as: adenocarcinoma of gallbladder · adenocarcinoma of the gallbladder · gall bladder adenocarcinoma · gallbladder adenocarcinoma

Data availability: 2 cell lines.

Disease family

This is a subtype of gallbladder carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › gallbladder cancer › gallbladder carcinoma › gallbladder adenocarcinoma

Related subtypes (4): gall bladder carcinoma in situ, gallbladder small cell neuroendocrine carcinoma, gallbladder squamous cell carcinoma, undifferentiated gallbladder carcinoma

Subtypes (4): gallbladder signet ring cell adenocarcinoma, gallbladder mucinous adenocarcinoma, gallbladder papillary neoplasm with an associated invasive carcinoma, gallbladder pleomorphic giant cell adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 16.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	10
PHASE1	4
PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05482516	PHASE3	RECRUITING	Evaluating Novel Therapies in ctDNA Positive GI Cancers
NCT07282912	PHASE2	RECRUITING	Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
NCT00085410	PHASE2	TERMINATED	Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
NCT00142480	PHASE2	COMPLETED	Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer
NCT00238212	PHASE2	COMPLETED	S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma
NCT00361231	PHASE2	COMPLETED	Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer
NCT00478140	PHASE2	TERMINATED	Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
NCT01093222	PHASE2	COMPLETED	Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
NCT01267344	PHASE2	COMPLETED	A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC
NCT01859182	PHASE2	WITHDRAWN	Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
NCT04931420	PHASE2	WITHDRAWN	Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
NCT00028496	PHASE1	COMPLETED	Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
NCT01643499	PHASE1	COMPLETED	Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
NCT01825603	PHASE1	COMPLETED	ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer
NCT03267940	PHASE1	TERMINATED	Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
NCT05430035	EARLY_PHASE1	RECRUITING	Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEVACIZUMAB	4	3
SORAFENIB	4	2
SELUMETINIB	4	1
PEGVORHYALURONIDASE ALFA	2	1
ADH-1	1	1
CHEMBL4463209	0	1